Tag: ATL


Daiichi Sankyo grabs first approval for blood cancer drug Ezharmia

September 26, 2022

Via: Pharmaphorum

The Ministry of Health, Labour and Welfare (MHLW) in Japan has cleared Ezharmia (valemetostat tosylate) based on the results of an open-label phase 2 trial which revealed a 48% overall response rate with the drug in previously-treated ATL patients. ATL […]